SPNT:NYSESiriusPoint Ltd. Analysis
Data as of 2026-05-26 - not real-time
$23.46
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
SiriusPoint is trading at $23.46, comfortably above its 20‑day SMA (23.27) and 50‑day SMA (22.59) while still below the 200‑day SMA (20.49), signaling a bullish price structure. The RSI sits near 55, indicating neutral momentum, but the MACD histogram has turned negative and the signal line is bearish, suggesting short‑term caution. Volume is on an increasing trend, and the stock is holding above the $21.76 support level with resistance near $24.32, leaving modest upside room.
Fundamentally, the company trades at a PE of 5.9 versus an industry average of 16.8, and its price‑to‑book of 1.18 is close to intrinsic book value, implying significant value discount. Recent Q1 2026 results showed $774.6 M revenue, $102.2 M net income, an improved core combined ratio of 88.9%, $71 M underwriting income and $240 M of capital returned through buybacks and preference‑share redemptions. Strong free cash flow ($467 M), low net debt, a ROE of 23% and rating upgrades further reinforce the upside narrative, while the DCF fair value of $70.6 suggests the market may be under‑pricing the stock by a wide margin.
Fundamentally, the company trades at a PE of 5.9 versus an industry average of 16.8, and its price‑to‑book of 1.18 is close to intrinsic book value, implying significant value discount. Recent Q1 2026 results showed $774.6 M revenue, $102.2 M net income, an improved core combined ratio of 88.9%, $71 M underwriting income and $240 M of capital returned through buybacks and preference‑share redemptions. Strong free cash flow ($467 M), low net debt, a ROE of 23% and rating upgrades further reinforce the upside narrative, while the DCF fair value of $70.6 suggests the market may be under‑pricing the stock by a wide margin.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Technical bullish trend with price above short‑term moving averages
- Increasing volume supporting price stability
- Strong Q1 earnings and capital return program
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervalued valuation metrics (PE, price‑to‑book) relative to peers
- Sustained underwriting profitability and rating upgrades
- Target price upside of ~15% to $27
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Exposure to catastrophe cycles inherent in reinsurance
- Robust balance sheet with low leverage and ample cash
- Absence of dividend but strong cash generation for future growth
Key Metrics & Analysis
Financial Health
Revenue Growth6.50%
Profit Margin16.51%
P/E Ratio5.9
ROE23.11%
ROA2.38%
Debt/Equity30.52
P/B Ratio1.2
Op. Cash Flow$333.2M
Free Cash Flow$467.2M
Industry P/E16.8
Technical Analysis
TrendBullish
RSI55.0
Support$21.76
Resistance$24.32
MA 20$23.27
MA 50$22.59
MA 200$20.49
MACDBearish
VolumeIncreasing
Fear & Greed Index91.57
Valuation
Fair Value$70.58
Target Price$27.00
Upside/Downside15.09%
GradeUndervalued
TypeBlend
Risk Assessment
Beta0.42
Volatility22.32%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.